A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants

Part of paid clinical trials in Daytona Beach, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT05841238
Phase
PHASE1
Status
Completed

Conditions

  • Healthy
  • Obese

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • LY3502970 — DRUG
    Administered orally.

Study Details

The main purpose of this study is to evaluate how much LY3502970 gets into the bloodstream and how long it takes the body to eliminate when administered orally as tablet and capsule formulations along with effect of food on LY3502970 in healthy overweight and obese participants. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study is conducted in two parts (part A and B) and will last up to 135 days including the screening period.

Key Dates

Start date
Apr 26, 2023
Status verified
Oct 2024
Primary completion
Sep 14, 2023
Completion
Nov 13, 2023

Study Design

Enrollment
52 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3502970 (Part A)
    The multiple doses of LY3502970 administered orally either in tablet or capsule formulations.
  • Experimental: LY3502970 (Part B)
    The multiple doses of LY3502970 administered orally in tablet formulation.

Primary Outcome Measure

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve from Time Zero to the 24 Hour Time Point (AUC[0-24]) of LY3502970 [ Time Frame: Predose up to 92 days postdose ]

Locations (3)

FacilityCityStateZIPSite coordinators
LabCorp CRU, Inc.Daytona BeachFlorida32117-
Labcorp Clinical Research LPDallasTexas75247-
LabCorp CRU, Inc.MadisonWisconsin53704-

Find similar trials in Daytona Beach, FL

By research site
LabCorp CRU, Inc.· Daytona Beach, FLLabcorp Clinical Research LP· Dallas, TXLabCorp CRU, Inc.· Madison, WI

Related Studies